

**Title:** Stem Cell Transplantation (Multiple Myeloma, Myelofibrosis, and Sickle Cell Disease) (CAG-00444R)

**Decision:** The Centers for Medicare & Medicaid Services (CMS) will expand national coverage for allogeneic hematopoietic stem cell transplantation (HSCT) for the three separate medical conditions listed below for certain Medicare beneficiaries with these conditions who participate in an approved prospective clinical study under coverage with evidence development.

- Multiple Myeloma
- Myelofibrosis, and
- Sickle Cell Disease

**What this means:** Allogeneic stem cell transplants for multiple myeloma, myelofibrosis and sickle cell disease may only be covered for members in CMS-approved prospective clinical studies. Please refer to the final decision memo for all coverage criteria.

**Effective:** January 27, 2016

This announcement can be found at: [Decision Memo for Stem Cell Transplantation \(Multiple Myeloma, Myelofibrosis, and Sickle Cell Disease\) \(CAG-00444R\)](#)

HealthPartners MSHO is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners Freedom is a Cost plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2462\_90242 IR Approved 06/2015  
H2422\_90242 IR Approved 07/2015